Xing-Qi Dong

Xing-Qi Dong

Auto-generated profile, based on publicly available information

Xing-Qi Dong

Yunnan Provincial Hospital of Infectious Disease/Yunnan AIDS Care Center, Kunming, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in BMC Public Health
Verified
Journal Article
Open access
PDF file
YLYouwang Lu
Youwang Lu
HLHuiqin Li
Huiqin Li
RDRongjing Dong
Rongjing Dong
MZMi Zhang
Mi Zhang
XDXingqi Dong
Xingqi Dong
JYJunchuan Ye
Junchuan Ye
Few studies have focused on the descriptive epidemiology and trends of HIV/AIDS since the publication of the Global Burden of Disease (GBD) study in 2021. Therefore, this study aims to analyze the trends and patterns of the HIV/AIDS burden at the global, regional, and national levels by sex, age and social development index (SDI). We also explored risk factors and predicted the GBD of HIV/AIDS until 2030. Data on the etiology of HIV/AIDS from 1990 to 2021 were collected from the 2021 GBD database. Estimated annual percent changes (EAPCs) were calculated to assess temporal trends in the age-standardized incidence rate (ASIR), age-standardized disability-adjusted life-year rate (ASDR) and age-standardized mortality rate (ASMR) of HIV/AIDS patients. Measures categorized by sex, region, age and SDI quintiles. In addition, an age‒period‒cohort model was established to forecast future trends of the HIV/AIDS burden to 2030. Globally, the incidence of HIV/AIDS reached 1.65 million (95% uncertainty interval 1.48 to 1.82) in 2021. From 1990 to 2021, the global ASIR of HIV/AIDS showed a downward trend, with an EAPC of 0.14% (0.12–0.16%). The ASIR, ASDR, and ASMR of HIV/AIDS were highest in the low-SDI region and lowest in the high-SDI region. Regionally, southern sub-Saharan Africa had the highest ASIR in 2021, whereas Oceania had the largest increase in the ASIR from 1990 to 2021. Burundi (EAPC 14.04%, 95% CI -13.63 to -14.44%), followed by Burkina Faso, exhibited the most significant decrease in the ASIR. Globally, the highest incidence rate was observed in the 25–29 years old group. Unsafe sex is the primary factor leading to the burden of HIV/AIDS. By 2030, the global ASIR, ASDR and ASMR of HIV/AIDS are expected to gradually decrease. HIV/AIDS disease burden varies by region, sex, and age. The global burden of HIV/AIDS is substantial in low-income regions, especially in Sub-Saharan Africa. Our study offers valuable epidemiological evidence for future research on the prevention and treatment of HIV/AIDS.

1 January 2008 in BMC Ecology
Verified
Journal Article
Open access
PDF file
JYJia-Xiang Yin
Jia-Xiang Yin
AGAlan Geater
Alan Geater
VCVirasakdi Chongsuvivatwong
Virasakdi Chongsuvivatwong
XDXing-Qi Dong
Xing-Qi Dong
CDChunhong DU
Chunhong DU
EMEdward McNeil
Edward McNeil
Ninety-one rodent plague epidemics have occurred in Lianghe county, Yunnan Province, China, between 1990 and 2006. This study aimed to identify predictors for the presence and abundance of small mammals in households of villages endemic for rodent plague in Lianghe county.

10 March 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XHXusheng Huang
Xusheng Huang
RTRen-Rong Tian
Ren-Rong Tian
MMMeng-Di Ma
Meng-Di Ma
RLRong-Hua Luo
Rong-Hua Luo
LYLiu-Meng Yang
Liu-Meng Yang
YZYong-Tang Zheng
Yong-Tang Zheng
Latent reservoir persistence remains a major obstacle for curing human immunodeficiency virus type 1 (HIV-1) infection. Thus, strategies for the elimination of latent HIV-1 are urgently needed. As a bromodomain and extra-terminal (BET) inhibitor, BMS-986158 has been used in clinical trials for advanced solid tumors and hematological malignancies. Here, we found that BMS-986158 reactivated latent HIV-1 in three types of HIV-1 latency cells in vitro, and in combination antiretroviral therapy (cART)-treated patient-derived peripheral blood mononuclear cells ex vivo, without influencing global immune cell activation. BMS-986158 reactivated latent HIV-1 by increasing phosphorylation of CDK9 at Thr186 and promoting recruitment of CDK9 and RNA polymerase II to the HIV-1 long terminal repeat in J-Lat cells. Furthermore, BMS-986158 exerted strong synergism in reactivating latent HIV-1 when combined with prostratin and vorinostat and enhanced the antiviral activity of anti-HIV-1 drugs. Finally, BMS-986158 showed antiviral activity in an HIV-1 acute infection model, possibly by arresting the cell cycle in infected cells. Thus, these results suggest that BMS-986158 is a potential candidate for AIDS/HIV-1 therapy.

30 August 2021 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
SHShizhen Huang
Shizhen Huang
CYCuixian Yang
Cuixian Yang
JXJiaying Xin
Jiaying Xin
RXRonghui Xie
Ronghui Xie
XYXinping Yang
Xinping Yang
LHLi Huiqin
Li Huiqin
Background: Injecting drugs is associated with a high risk of HIV infection, alongside the risk of a drug overdose and mental health problems. Objective: To evaluate the effect of methadone maintenance treatment (MMT) combined with rilpivirine (RPV)-based regimens on drug use of HIV individuals. Methods: This study was a prospective, open-label, controlled, drug-drug interaction trial at a single center for 24 weeks. Participants on stable MMT were randomly divided into two groups administered RPV/TDF/3TC (RPV group) and EFV/TDF/3TC (EFV group), respectively. Adjustment doses of methadone were monitored for 12 weeks. HIV-1 RNA was used to evaluate the effects of antiretroviral therapy at week 24. Acute opioid withdrawal-, drug craving questionnaire- and MOSHIV scales were used to assess study outcomes. Results: 22 and 18 cases of HIV-infected drug users were recruited in the RPV and EFV groups, respectively. Thirty-one cases had completed monitoring and clinical evaluation at week 24. In the RPV and EFV groups, 32% and 56% of the participants had methadone dose adjustment, respectively, indicating a significantly lower rate in the RPV group. The rates of individuals with HIV RNA levels from 50-500 copies/ml were 94% (RPV group) and 90% (EFV group). The drug craving questionnaire scale scores decreased in both groups. After one week of treatments, acute opioid withdrawal scale scores increased in both groups, with no significant difference between them. Conclusion: Concomitant administration of RPV does not significantly affect methadone and could decrease withdrawal symptoms. An RPV-based regimen may be used as first-line treatment in IDUs with HIV infection.